Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Pérez-Ruiz, Elísabeth; Minute, Luna; Otano, Itziar; Álvarez, Maite; C. Ochoa, María; Belsúe, Virginia; de Andrea, Carlos; E. Rodríguez-Ruiz, María; Luis Perez‐Gracia, José; Márquez‐Rodas, Iván; Llácer, Casilda; Álvarez, Martina; de Luque, Vanesa; Molina, Carmen; Teijeira, Álvaro; Berraondo, Pedro; Melero, Ignacio

doi:10.1038/s41586-019-1162-y

Public

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Published in Nature • May 1, 2019

Authors:

Elísabeth Pérez-Ruiz

Luna Minute

Itziar Otano

Abstract

Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer1–3. However, this comes at the cost of frequent, serious immune-related adverse events, necessitating a reduction in the recommended dose o...

Subject

Ipilimumab

Nivolumab

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!